# US 2023/0323428 A1 · Compositions and methods of rna analysis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0323428 A1
- Document ID: US20230323428A1
- Status: Published application
- Kind: A1
- Application number: 18/209,992
- Filed: 2023-06-14
- Published: 2023-10-12
- Earliest claimed: 2015-07-24
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Harry Benjamin Larman; Joel Credle
- Web page: https://patentgrep.com/patent/US20230323428A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/68: involving nucleic acids
- C12Q 2521/327: RNAse, e.g. RNAseH
- C12Q 2521/501: Ligase
- C12Q 2523/109: chemical ligation between nucleic acids
- C12Q 2525/155: incorporating/generating a new priming site
- C12Q 2525/161: incorporating target specific and non-target specific sites
- C12Q 2525/204: specific length of the oligonucleotides
- C12Q 2535/122: Massive parallel sequencing
- C12Q 2543/10: the purpose being "in situ" analysis
- C12Q 2565/125: Electrophoretic separation
- C12Q 2565/627: being a mass spectrometer
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure relates to compositions and methods of RNA analysis. In particular, the present disclosure provides a method of RNA analysis that includes obtaining a sample, applying one or more multi-partite probes to the sample, where each of the one or more multi-partite probes includes at least two sub-probes, annealing at least one of the applied one or more multi-partite probes to at least one target nucleic acid within the sample, and ligating the at least two sub-probes associated with the at least one annealed multi-partite probe to create a target nucleic acid proxy that can be detected.

## Claims

### Claim 1

A method, comprising:
obtaining a sample;
applying one or more multi-partite probes to the sample, wherein each of the one or more multi-partite probes includes at least two sub-probes;
annealing at least one of the applied one or more multi-partite probes to at least one target nucleic acid within the sample; and
ligating the at least two sub-probes associated with the at least one annealed multi-partite probe to create a target nucleic acid proxy that can be detected.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
releasing the target nucleic acid proxy from the target nucleic acid; and
amplifying the target nucleic acid proxy.

### Claim 3 (depends on 1)

The method of claim 1, wherein the at least one target nucleic acid is RNA.

### Claim 4 (depends on 1)

The method of claim 1, wherein the sub-probes comprise appended primer binding sites to facilitate subsequent amplification of the target nucleic acid proxy.

### Claim 5 (depends on 1)

The method of claim 1, wherein the at least two sub-probes are ligated with an enzyme, a chemical reaction, or a photoreaction.

### Claim 6 (depends on 5)

The method of claim 5, wherein the enzyme is a ligase.

### Claim 7 (depends on 6)

The method of claim 6, wherein the ligase is selected from the group consisting of a T4 RNA Ligase 2 (Rn12), T4 DNA ligase, a Chlorella virus DNA Ligase (PBCV-1 DNA Ligase), a Rn12 derivative, PBCV-1derivative, and any combination thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein each sub-probe comprises an oligonucleotide.

### Claim 9 (depends on 1)

The method of claim 1, wherein at least one of the sub-probes is a DNA oligonucleotide that has a 3′-termination of at least two RNA bases.

### Claim 10 (depends on 1)

The method of claim 1, wherein the at least one of the sub-probes is a DNA oligonucleotide that has a 5′-phosphorylation.

### Claim 11 (depends on 1)

The method of claim 1, wherein the sample is selected from the group consisting of a cell, an organ, a tissue, and any combination thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the sample is a formalin fixed paraffin embedded (FFPE) tissue sample.

### Claim 13 (depends on 11)

The method of claim 11, wherein the sample is fixed using non-formalin reagents.

### Claim 14

(canceled)

### Claim 15 (depends on 11)

The method of claim 11, wherein the sample is comprised of fixed cells in suspension.

### Claim 16 (depends on 11)

The method of claim 11, wherein the sample is a fixed tissue culture.

### Claim 17

(canceled)

### Claim 18 (depends on 2)

The method of claim 2, wherein the target nucleic acid proxy is released from the target nucleic acid by an endonuclease or recovered by denaturing the target nucleic acid proxy containing the at least two ligated sub-probes.

### Claim 19 (depends on 18)

The method of claim 18, wherein the endonuclease comprises an RNase H, RNaseA, RNase If, or RNaseHIII.

### Claim 20 (depends on 19)

The method of claim 19, wherein the RNase H comprises RNase H1, RNase H2, RNAse H2 and RNAse HII.

### Claim 21 (depends on 2)

The method of claim 2, wherein the amplified target nucleic acid proxy is analyzed using a technique selected from the group consisting of Next Generation Sequencing (NGS), Deep Sequencing, mass spectrometry based sequence or length analysis, DNA fragment sequence or length analysis by gel electrophoresis or capillary electrophoresis, and hybridization on immobilized detection probes.

### Claim at position 22

22-32. (canceled)

### Claim 33

A method, comprising:
obtaining a fixed tissue sample from a subject;
applying one or more multi-partite probes to the fixed tissue sample, wherein each of the one or more multi-partite probes includes at least two sub-probes;
annealing at least one of the one or more applied multi-partite probes to a target nucleic acid within the fixed tissue sample;
ligating the at least two sub-probes associated with the at least one annealed multi-partite probe to create a target nucleic acid proxy within the fixed tissue sample; and
stamping the ligated probes onto a replica surface coated with a plurality of immobilized PCR primers.

### Claim at position 24

34-41. (canceled)
